Myasthenia gravis: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• CD19 13
• BCMA 13
• CD20 3
• PD-1 0
• CD40 0
• JAK 0
• AKT 0
• HIF-1 0
• IL-17 0
• mTOR 0
• PI3K 0
• AMPK 0
• AQP4 1
• COX-2 0
• GPX4 0
• HER2 0
• HMGB1 0
• IL-1 0
• IL-6 0
• MAPK 0
• NLRP3 0
• PD-L1 0
• PSMA 0
• SGLT2 0
• STAT3 0
• STING 0

EU-13 is a filter, not a ranking: it only narrows the list.

20 of 20+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Trials whose registry record says individual participant data (IPD) will be shared.

• A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)

  NCT06220201· Juno Therapeutics, Inc., a Bristol-Myers Squibb Company· Source

• Safety and Efficacy of CD19-BCMA Targeted CAR-T Therapy for Refractory Generalized Myasthenia Gravis

  NCT06371040· Ting Chang, MD· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 9
• Mendelian Randomization Analysis 9
• Gene Expression Profiling 5
• Sequence Analysis, RNA 3
• Exome Sequencing 1
• Proteomics 8
• Metabolomics 6
• Flow Cytometry 4
• Immunohistochemistry 1
• Magnetic Resonance Imaging 10
• Machine Learning 8
• Cohort Studies 37
• Genome-Wide Association Study 10

• Data-augmented machine learning refines the effective-concentration estimate for eculizumab in complement-mediated diseases.

  Front Immunol, Jul 2026

• Proteomic and machine learning analysis predicts treatment response signatures in Myasthenia Gravis.

  J Transl Med, Jun 2026

• CFD+CD14+ monocytes: potential pathogenic subset in myasthenia gravis uncovered by multi-omics integration and machine learning analysis.

  Front Immunol, May 2026

• Interpretable machine learning model predicts postoperative complications after thoracoscopic mediastinal tumor surgery: a multicenter study.

  BMC Med Inform Decis Mak, Mar 2026

• Increased Prevalence of Extrathymic Neoplasms in Myasthenia Gravis Patients-A Population-Based, Matched Case-Control Study.

  Muscle Nerve, Mar 2026

• Long COVID as an independent predictor of myasthenia gravis exacerbation: A prospective cohort study integrating machine learning for risk stratification.

  Respir Med, Nov 2025

• Building a Quantitative Telemedicine Platform for Myasthenia Gravis: Augmenting the Physical Examination.

  Muscle Nerve, Nov 2025

• Prediction of Myasthenia Gravis Worsening: A Machine Learning Algorithm Using Wearables and Patient-Reported Measures.

  Ann Clin Transl Neurol, Nov 2025

See which targets of this disease your abstract mentions, and go to the people working on them.